FR2515177A1 - Nouveaux derives de 1-(aminophenyl)-2-amino-1-ethanol, leur procede de preparation et leur utilisation en therapeutique - Google Patents
Nouveaux derives de 1-(aminophenyl)-2-amino-1-ethanol, leur procede de preparation et leur utilisation en therapeutique Download PDFInfo
- Publication number
- FR2515177A1 FR2515177A1 FR8120249A FR8120249A FR2515177A1 FR 2515177 A1 FR2515177 A1 FR 2515177A1 FR 8120249 A FR8120249 A FR 8120249A FR 8120249 A FR8120249 A FR 8120249A FR 2515177 A1 FR2515177 A1 FR 2515177A1
- Authority
- FR
- France
- Prior art keywords
- sep
- amino
- ethanol
- crl
- chlorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 butyl-amino 1-ethanol Chemical compound 0.000 title claims abstract description 44
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 title claims abstract description 7
- 230000000694 effects Effects 0.000 title abstract description 23
- 239000000935 antidepressant agent Substances 0.000 title abstract description 12
- 229940005513 antidepressants Drugs 0.000 title abstract description 11
- 230000001077 hypotensive effect Effects 0.000 title abstract description 7
- 208000001953 Hypotension Diseases 0.000 title abstract description 5
- 239000000932 sedative agent Substances 0.000 title abstract description 5
- 208000021822 hypotensive Diseases 0.000 title abstract description 4
- 230000005284 excitation Effects 0.000 title abstract description 3
- 229940125723 sedative agent Drugs 0.000 title abstract 2
- 229940124549 vasodilator Drugs 0.000 title description 6
- 239000003071 vasodilator agent Substances 0.000 title description 6
- 230000009257 reactivity Effects 0.000 title description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 239000002253 acid Substances 0.000 claims abstract description 10
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 7
- 229940009098 aspartate Drugs 0.000 claims abstract description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims abstract description 6
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 claims abstract description 4
- WSFXXTPRWQDYPT-UHFFFAOYSA-N 2-amino-1-(2-aminophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1N WSFXXTPRWQDYPT-UHFFFAOYSA-N 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 44
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 11
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000006722 reduction reaction Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 4
- 125000000068 chlorophenyl group Chemical group 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000013067 intermediate product Substances 0.000 claims 2
- LZAMLBFWTLFDKM-UHFFFAOYSA-N 1-(propan-2-ylamino)ethanol Chemical compound CC(C)NC(C)O LZAMLBFWTLFDKM-UHFFFAOYSA-N 0.000 claims 1
- UJPKMTDFFUTLGM-UHFFFAOYSA-N 1-aminoethanol Chemical compound CC(N)O UJPKMTDFFUTLGM-UHFFFAOYSA-N 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 230000035874 hyperreactivity Effects 0.000 abstract description 3
- 239000000810 peripheral vasodilating agent Substances 0.000 abstract description 2
- 229960002116 peripheral vasodilator Drugs 0.000 abstract description 2
- YFWZJAJAHWEVAQ-UHFFFAOYSA-N C(C=CC(=O)O)(=O)O.NC1=CC=C(C=C1)C(CNC(C)C)O Chemical compound C(C=CC(=O)O)(=O)O.NC1=CC=C(C=C1)C(CNC(C)C)O YFWZJAJAHWEVAQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 230000009471 action Effects 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 230000004899 motility Effects 0.000 description 13
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 12
- 229960004046 apomorphine Drugs 0.000 description 12
- 210000003169 central nervous system Anatomy 0.000 description 12
- 230000002631 hypothermal effect Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 description 11
- 206010039897 Sedation Diseases 0.000 description 10
- 230000001430 anti-depressive effect Effects 0.000 description 10
- 230000036280 sedation Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 9
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 9
- 229960003147 reserpine Drugs 0.000 description 9
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 9
- 230000003993 interaction Effects 0.000 description 8
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 7
- 206010021143 Hypoxia Diseases 0.000 description 7
- 206010042008 Stereotypy Diseases 0.000 description 7
- 229940025084 amphetamine Drugs 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 230000006399 behavior Effects 0.000 description 7
- 239000012458 free base Substances 0.000 description 7
- 206010002660 Anoxia Diseases 0.000 description 6
- 241000976983 Anoxia Species 0.000 description 6
- 230000007953 anoxia Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 206010044565 Tremor Diseases 0.000 description 4
- 230000016571 aggressive behavior Effects 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 230000001631 hypertensive effect Effects 0.000 description 4
- 230000001624 sedative effect Effects 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- 206010015995 Eyelid ptosis Diseases 0.000 description 3
- 206010039424 Salivary hypersecretion Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000002920 convulsive effect Effects 0.000 description 3
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 description 3
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 230000037023 motor activity Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 201000003004 ptosis Diseases 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 208000026451 salivation Diseases 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- BHURBFXYVURCEV-UHFFFAOYSA-N 1-(4-aminophenyl)-2-(propan-2-ylamino)ethanol Chemical compound CC(C)NCC(O)C1=CC=C(N)C=C1 BHURBFXYVURCEV-UHFFFAOYSA-N 0.000 description 2
- KDNSFFWWJRCSKD-UHFFFAOYSA-N 2-(tert-butylamino)-1-(3-nitrophenyl)ethanol;hydrochloride Chemical compound Cl.CC(C)(C)NCC(O)C1=CC=CC([N+]([O-])=O)=C1 KDNSFFWWJRCSKD-UHFFFAOYSA-N 0.000 description 2
- LZCQQYQFJPLEBE-UHFFFAOYSA-N 2-bromo-1-(4-nitrophenyl)ethanol Chemical compound BrCC(O)C1=CC=C([N+]([O-])=O)C=C1 LZCQQYQFJPLEBE-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- STGOXRVTUNXXLQ-UHFFFAOYSA-N [2-hydroxy-2-(4-nitrophenyl)ethyl]-propan-2-ylazanium;chloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C([N+]([O-])=O)C=C1 STGOXRVTUNXXLQ-UHFFFAOYSA-N 0.000 description 2
- 230000002539 anti-aggressive effect Effects 0.000 description 2
- MOIPGXQKZSZOQX-UHFFFAOYSA-N carbonyl bromide Chemical compound BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 230000004046 hyporesponsiveness Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- CAQZTSCRGMRSHX-TYYBGVCCSA-N (e)-but-2-enedioic acid;ethanol Chemical compound CCO.OC(=O)\C=C\C(O)=O CAQZTSCRGMRSHX-TYYBGVCCSA-N 0.000 description 1
- ZUYWFUUNQDJUKG-UHFFFAOYSA-N 1-(butylamino)ethanol Chemical compound CCCCNC(C)O ZUYWFUUNQDJUKG-UHFFFAOYSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- OFQCQIGMURIECL-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl]-2',6'-dimethylspiro[isoquinoline-4,4'-oxane]-1,3-dione;phosphoric acid Chemical compound OP(O)(O)=O.O=C1N(CCN(CC)CC)C(=O)C2=CC=CC=C2C21CC(C)OC(C)C2 OFQCQIGMURIECL-UHFFFAOYSA-N 0.000 description 1
- GGHMLSGJPIBJRA-UHFFFAOYSA-N 2-bromo-1-(3-nitrophenyl)ethanol Chemical compound BrCC(O)C1=CC=CC([N+]([O-])=O)=C1 GGHMLSGJPIBJRA-UHFFFAOYSA-N 0.000 description 1
- LNXQINFBHSFJDT-UHFFFAOYSA-N 2-bromo-1-(4-chloro-3-nitrophenyl)ethanol Chemical compound BrCC(O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 LNXQINFBHSFJDT-UHFFFAOYSA-N 0.000 description 1
- KTHNITVDTYAHFF-UHFFFAOYSA-N 2-chloro-4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C(Cl)=C1 KTHNITVDTYAHFF-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- XLNHMRASGSGFAG-DKWTVANSSA-N N[C@@H](CC(=O)O)C(=O)O.C(C)O Chemical compound N[C@@H](CC(=O)O)C(=O)O.C(C)O XLNHMRASGSGFAG-DKWTVANSSA-N 0.000 description 1
- 206010035039 Piloerection Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- ICLWTJIMXVISSR-UHFFFAOYSA-N gallamine Chemical compound CCN(CC)CCOC1=CC=CC(OCCN(CC)CC)=C1OCCN(CC)CC ICLWTJIMXVISSR-UHFFFAOYSA-N 0.000 description 1
- 229960003054 gallamine Drugs 0.000 description 1
- REEUVFCVXKWOFE-UHFFFAOYSA-K gallamine triethiodide Chemical compound [I-].[I-].[I-].CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC REEUVFCVXKWOFE-UHFFFAOYSA-K 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000035873 hypermotility Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- HWYHDWGGACRVEH-UHFFFAOYSA-N n-methyl-n-(4-pyrrolidin-1-ylbut-2-ynyl)acetamide Chemical compound CC(=O)N(C)CC#CCN1CCCC1 HWYHDWGGACRVEH-UHFFFAOYSA-N 0.000 description 1
- UAORFCGRZIGNCI-UHFFFAOYSA-N nifenalol Chemical compound CC(C)NCC(O)C1=CC=C([N+]([O-])=O)C=C1 UAORFCGRZIGNCI-UHFFFAOYSA-N 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000005371 pilomotor reflex Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000002385 vertebral artery Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
- C07C205/26—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups and being further substituted by halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
- C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
- C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
- C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
- C07C217/70—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
- C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
- C07C29/143—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of ketones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8120249A FR2515177A1 (fr) | 1981-10-28 | 1981-10-28 | Nouveaux derives de 1-(aminophenyl)-2-amino-1-ethanol, leur procede de preparation et leur utilisation en therapeutique |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8120249A FR2515177A1 (fr) | 1981-10-28 | 1981-10-28 | Nouveaux derives de 1-(aminophenyl)-2-amino-1-ethanol, leur procede de preparation et leur utilisation en therapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2515177A1 true FR2515177A1 (fr) | 1983-04-29 |
| FR2515177B1 FR2515177B1 (enExample) | 1984-10-12 |
Family
ID=9263492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8120249A Granted FR2515177A1 (fr) | 1981-10-28 | 1981-10-28 | Nouveaux derives de 1-(aminophenyl)-2-amino-1-ethanol, leur procede de preparation et leur utilisation en therapeutique |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2515177A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0146738A3 (en) * | 1983-12-23 | 1987-07-29 | American Cyanamid Company | Antimicrobial animal feed additive compositions |
| WO2001017962A1 (en) * | 1999-09-03 | 2001-03-15 | Asahi Kasei Kabushiki Kaisha | Processes for the preparation of tricyclic amino alcohol derivatives |
| CN110143886A (zh) * | 2019-05-10 | 2019-08-20 | 北京化工大学 | 制备如妥洛特罗、氯丙那林、二氯异丙肾上腺素和索他洛尔的β-芳基氨基醇类药物的方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1561863A (enExample) * | 1967-05-09 | 1969-03-28 | ||
| FR2210414A1 (enExample) * | 1972-12-18 | 1974-07-12 | Thomae Gmbh Dr K | |
| JPS5363333A (en) * | 1976-11-12 | 1978-06-06 | Hokuriku Pharmaceutical | Nitro grouppsubstituted 22chlorobenzylalcohol derivative and process for preparing same |
| JPS5363332A (en) * | 1976-11-12 | 1978-06-06 | Hokuriku Pharmaceutical | Amino grouppsubstituted 22chlorobenzylalcohol derivative and process for preparing same |
-
1981
- 1981-10-28 FR FR8120249A patent/FR2515177A1/fr active Granted
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1561863A (enExample) * | 1967-05-09 | 1969-03-28 | ||
| FR2210414A1 (enExample) * | 1972-12-18 | 1974-07-12 | Thomae Gmbh Dr K | |
| JPS5363333A (en) * | 1976-11-12 | 1978-06-06 | Hokuriku Pharmaceutical | Nitro grouppsubstituted 22chlorobenzylalcohol derivative and process for preparing same |
| JPS5363332A (en) * | 1976-11-12 | 1978-06-06 | Hokuriku Pharmaceutical | Amino grouppsubstituted 22chlorobenzylalcohol derivative and process for preparing same |
Non-Patent Citations (4)
| Title |
|---|
| CA1953 * |
| CA1968 * |
| CA1978 * |
| EXBK/72 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0146738A3 (en) * | 1983-12-23 | 1987-07-29 | American Cyanamid Company | Antimicrobial animal feed additive compositions |
| WO2001017962A1 (en) * | 1999-09-03 | 2001-03-15 | Asahi Kasei Kabushiki Kaisha | Processes for the preparation of tricyclic amino alcohol derivatives |
| US6696573B1 (en) | 1999-09-03 | 2004-02-24 | Asahi Kasei Kabushiki Kaisha | Processes for the preparation of tricyclic amino alcohol derivatives |
| CN110143886A (zh) * | 2019-05-10 | 2019-08-20 | 北京化工大学 | 制备如妥洛特罗、氯丙那林、二氯异丙肾上腺素和索他洛尔的β-芳基氨基醇类药物的方法 |
| CN110143886B (zh) * | 2019-05-10 | 2022-11-01 | 北京化工大学 | 制备如妥洛特罗、氯丙那林、二氯异丙肾上腺素和索他洛尔的β-芳基氨基醇类药物的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2515177B1 (enExample) | 1984-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0097071B1 (fr) | Dérivés de benzhydrylsulfinylacétamide et leur utilisation en thérapeutique | |
| EP0192521B1 (fr) | Dérivés de 3-phényl-tétrahydropyridine, procédé de préparation et utilisation en thérapeutique | |
| EP0097547B1 (fr) | Acides halogénobenzhydrylsulfinylacétohydroxamiques, procédé de préparation et utilisation en thérapeutique | |
| FR2511366A1 (fr) | Nouveaux derives de la pyridazine, leur procede de preparation et les medicaments, actifs sur le systeme nerveux central, qui en contiennent | |
| CH619935A5 (enExample) | ||
| FR2534915A1 (fr) | Nouveaux derives de 2-(phenoxymethyl)-morpholine, utilisation en therapeutique et procede de preparation | |
| FR2515177A1 (fr) | Nouveaux derives de 1-(aminophenyl)-2-amino-1-ethanol, leur procede de preparation et leur utilisation en therapeutique | |
| EP0061406B1 (fr) | Dérivés d'acide benzamido-alkyl-hydroxamique, procédé de préparation et composition thérapeutique | |
| FR2625502A1 (fr) | Nouveaux derives du 3-piperidine carbaldehyde oxime, leur procede de preparation et leur application comme medicaments | |
| CH622795A5 (enExample) | ||
| EP0138716B1 (fr) | Nouveaux dérivés de 2-tolyl-morpholine utiles en thérapeutique | |
| EP0143711B1 (fr) | Dérivés de N-(méthoxyphénacyl)-amine, utilisation notamment en thérapeutique et procédé de préparation | |
| FR2486074A1 (fr) | Derives de fluorophenacyl-amine, leur procede de preparation et leur application en therapeutique | |
| FR2517305A1 (fr) | Nouveaux derives de 2-phenyl-morpholine et leur utilisation en therapeutique | |
| EP0097546B1 (fr) | Benzhydrylsulfinyléthylamines, procédé de préparation et utilisation en thérapeutique | |
| EP0158545B1 (fr) | Dérivés d'acide [alpha-(alkylaminométhyl)-benzylthio]-acétique, procédé de préparation et utilisation en thérapeutique | |
| EP0138715B1 (fr) | Dérivés de N-(4-acétylaminophénacyl)-amine, leur utilisation en thérapeutique et leur procédé de préparation | |
| CA1063619A (fr) | Procede de preparation de nouveaux acides benzylamino alcanoiques et les produits qui en resultent | |
| FR2460668A1 (fr) | Derives de 2-amino-1-phenyl-1-ethanol, utiles en tant que medicaments et leur procede de preparation | |
| FR2553411A1 (fr) | Derives de 2-halogenophenyl-morpholine, procede de preparation et utilisation en therapeutique | |
| EP0060954B1 (fr) | Dérivés de fluorophénacyl-amine, et leur application en thérapeutique | |
| EP0174887B1 (fr) | Dérivés de 1-[N-(alpha-amino-alpha-méthylacétyl)-aminophényl]-2-amino-propanone, procédé de préparation et utilisation en thérapeutique | |
| BE874322R (fr) | Nouveaux composes heterocycliques, leur preparation et leur application comme medicaments | |
| FR2946344A1 (fr) | Nouveaux derives d'aryl-{4-halogeno-4-[aminomethyl]-piperidin-1-yl} methanone, leur procede de preparation et leur utilisation a titre de medicaments | |
| FR2553412A1 (fr) | Derives de 4-alkyl-2-methyl-2-phenyl-morpholine, procede de preparation et utilisation en therapeutique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |